Novavax | NVAX - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Adma Biologics USD 50.29M 12.46M 2026-03
Agenus USD 15.05M 656K 2026-03
AstraZeneca USD 3.16B 3.95B 2026-06
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
Cassava Sciences USD -11.17M 2.38M 2026-03
Geron USD -236K 10.55M 2026-03
GlaxoSmithKline GBP 2.6B 312M 2026-06
MannKind USD -68.23M 8.76M 2026-06
Merck USD 840M 2.72B 2026-06
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Moderna USD -815M 573M 2026-06
Novartis USD 4.24B 171M 2026-03
Novavax USD 20.94M 100.32M 2025-12
Pfizer USD 667M 4.32B 2026-06
Sanofi EUR 2.38B 449M 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
TG Therapeutics USD 21.67M 13.12M 2026-06